Thymic epithelial tumor

Thymic epithelial tumor (TET) is a rare type of tumor that arises from the glandular cells of the thymus, the organ responsible for the development and maturation of T-lymphocytes, key cells of the immune system. These tumors can be either benign or malignant, with the latter being the most dangerous and difficult to manage clinically. The main signs of the disease may include symptoms of pressure on adjacent structures, such as cough, difficulty breathing, chest pain, and distension behind the breastbone. Thymic epithelial tumor has a variety of morphological forms, the most well-known of which are thymomas and myxomas, each of which requires a special approach to diagnosis and treatment.

History of the disease and interesting historical facts

Thymic tumors first came to the attention of physicians in the early 20th century, when it was noted that their occurrence was associated with differences in the clinical course of diseases in young and old people. In the 1900s, the study of the thymus began in the context of its role in the development of the immune system, which became the basis for further research into thymic tumors. In the 1930s, surgeons began to actively remove thymomas, which marked the beginning of the development of surgical therapy for this disease. Interestingly, thymoma is even mentioned in ancient medical texts, although not in the context in which we understand it today. The first descriptions of thymus tumors that were collected and systematized occurred after World War II, when doctors began to pay attention to the increase in the incidence of tumors associated with radiation exposure.

Epidemiology

According to studies, the incidence of thymic epithelial tumors is approximately 0.2-1% of all breast tumors. Thymomas are usually diagnosed in people between the ages of 40 and 70 years, with a higher incidence in men than in women in a ratio of approximately 2:1. An important aspect of epidemiology is the association of thymomas with some autoimmune diseases, such as myasthenia gravis, which is observed in 10-20% patients with thymoma. In addition, populations with high levels of radiation exposure, such as those affected by atomic bombs, have been reported to have increased incidence rates of thymic tumors.

Genetic predisposition to this disease

Genetic studies show that some mutations in genes involved in cell proliferation and apoptosis may be associated with the development of thymic epithelial tumors. In particular, mutations in the TP53, K-RAS, and H-RAS genes play an important role in the pathogenesis of thymomas. It has also been established that polymorphisms in genes associated with the immune response may increase the risk of autoimmune diseases associated with thymoma. The presence of a hereditary predisposition should be taken into account in family analysis and assessment of the risk of the disease in relatives.

Risk factors for the development of this disease

Among the risk factors that contribute to the development of thymic epithelial tumor are:

• Radiation: Exposure to ionizing radiation can cause mutations that promote tumor formation.
• Autoimmune diseases: Having diseases such as myasthenia gravis, systemic lupus erythematosus, and Hashimoto's thyroiditis has been associated with an increased risk of developing thymomas.
• Biological factors: Viral infections such as Epstein-Barr virus may play a role in the pathogenesis of some types of thymomas.
• Age: Increasing age is a significant risk factor, as most cases of the disease occur in people over 40 years of age.
• Gender: Men are affected more often than women.

Diagnosis of this disease

Diagnosis of thymic epithelial tumor includes several stages:

• The main symptoms are: chest pain, cough, difficulty breathing, a feeling of distension behind the breastbone, which may indicate compression around the tumor.
• Laboratory tests: Determination of markers such as anti-acetylcholine receptor in patients with myasthenia gravis may be useful.
• Radiological examinations: computed tomography and magnetic resonance imaging provide visualization of the tumor, as well as an assessment of its size and extent.
• Other types of diagnostics of the disease: endoscopy and biopsy may be necessary for morphological analysis of tissue.
• Differential diagnosis: Ruling out other causes of similar symptoms, such as lung cancer or lymphoma, is important to make an accurate diagnosis.

Treatment

Treatment of thymic epithelial tumor depends on its type, stage, and the patient's overall condition. The main approaches include:

• General treatment: Surgical removal of the tumor is the main method, especially in the early stages.
• Pharmacological treatment: may include the use of chemotherapy and/or radiotherapy in the postoperative period or when the disease recurs.
• Surgical treatment: requires careful consideration and is often used for localized forms of the tumor.
• Other treatments: Immunotherapy and targeted therapy may be considered in difficult clinical situations.

List of medications used to treat this disease

Medications used to treat thymic epithelial tumor may include:

• Doxorubicin: used for chemotherapy of malignant tumors.
• Cisplatin: Also used as part of chemotherapy.
• Etoposide: Often included in treatment regimens for relapses or metastases.
• Trastuzumab: Used in some cases to treat a tumor that has certain molecular characteristics.

Disease monitoring

Post-treatment monitoring of thymic epithelial tumor includes regular observation of symptoms, laboratory and radiological examinations for early detection of possible recurrences. Control stages are usually carried out:

• Every 3-6 months for the first two years after treatment.
• Every 6-12 months in subsequent years.

The prognosis depends on the stage of the disease and the presence of comorbidities. Studies show that five-year survival in early stages can reach 90%, while in advanced cases it decreases to 30%.

Age-related features of the disease

Thymic epithelial tumor has its own characteristics depending on the patient's age. In children and adolescents, predominantly benign tumors occur, most often thymomas, which have a favorable prognosis. In adults, especially the elderly, malignant forms are even more common, which can significantly worsen the prognosis and complicate treatment.

Questions and Answers

• What is thymic epithelial tumor?
  Thymic epithelial tumor is a tumor that arises from a cell of the thymus, can be either benign or malignant, and affects the functions of the immune system.
• What are the main symptoms of thymic epithelial tumor?
  The main symptoms include difficulty breathing, cough, chest pain and discomfort behind the breastbone.
• How is thymic epithelial tumor diagnosed?
  Diagnosis includes symptoms, laboratory tests, radiological methods, biopsy and differential diagnosis to exclude other diseases.
• What treatment is used for this disease?
  Treatment may include surgical removal of the tumor, chemotherapy, radiation therapy, and in some cases immunotherapy.
• What is the prognosis for thymic epithelial tumor?
  The prognosis depends on the stage of the disease, but in the early stages, five-year survival can be as high as 90%.